Gillison ML, Blumenschein G, Jr., and Fayette J, et al (2018) CheckMate 141: 1-year update and subgroup analysis of nivolumab as first-line therapy in patients with recurrent/metastatic head and neck cancer Oncologist 23 (9) 10791082 PMID: 29866947 PMCID: 6221824 6
We can add glutathione to several of our IV Therapy packages for an additional $40
A PRP facial combined with a peptide protocol addressing collagen synthesis will typically produce better long-term outcomes than either approach used in isolation
The program serves patients across Dallas, Fort Worth, Plano, Colleyville, Argyle, Waxahachie, The Woodlands, Austin, and through telehealth across Texas